Form 4: Tarsus Pharmaceuticals Director Morrison Settles Restricted Stock Units
SEC Form 4
Director Scott W. Morrison settled restricted stock units (RSUs) of Tarsus Pharmaceuticals, Inc. on June 24, 2024, acquiring 4,683 shares of common stock.
Summary
- On June 24, 2024, Scott W. Morrison, a director of Tarsus Pharmaceuticals, Inc., settled 3,350 Restricted Stock Units (RSUs).
- This resulted in the acquisition of 4,683 shares of common stock.
- The RSUs were granted on June 22, 2023, and vested on the one-year anniversary, contingent upon continuous service as a non-employee director.
- The reporting person now directly owns the acquired shares.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (RSU settlement) by a company director, suggesting a neutral sentiment. It doesn't indicate any significant positive or negative developments for the company.
Positives
- The vesting and settlement of RSUs indicate confidence in the company's future by a director.
Industry Context
Form 4 filings are routine and provide transparency into the transactions of company insiders, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/22/2023 | RSUs granted to the Reporting Person |
| 06/24/2024 | Date of RSU settlement and stock acquisition |
| 06/25/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.